Stock ORX OREXO AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Orexo AB

Equities

ORX

SE0000736415

Pharmaceuticals

Delayed Nasdaq Stockholm
Other stock markets
 09:35:50 2024-04-23 am EDT 		5-day change 1st Jan Change
16.58 SEK +5.07% Intraday chart for Orexo AB -2.01% +7.24%
Apr. 17 Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment MT
Apr. 17 Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US CI

Business Summary

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Number of employees: 116

Sales per Business

SEK in Million2022Weight2023Weight Delta
US Pharma
90.4 %
571 91.5 % 578 90.4 % +1.10%
HQ & Pipeline
9.6 %
53 8.4 % 61 9.6 % +16.16%
Digital Mental Health Programs
0.0 %
0 0.1 % 0 0.0 % -75.00%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
90.8 %
574 92.0 % 580 90.8 % +0.99%
European Union
8.6 %
46 7.3 % 55 8.6 % +20.61%
Rest of the World
0.6 %
5 0.7 % 4 0.6 % -11.11%

Managers

Managers TitleAgeSince
Nikolaj Sørensen CEO
 Chief Executive Officer 52 11-09-30
Fredrik Järrsten DFI
 Director of Finance/CFO 57 22-08-31
Edward Kim CTO
 Chief Tech/Sci/R&D Officer - 22-10-25
Robert Rönn CTO
 Chief Tech/Sci/R&D Officer 48 16-12-31
Cecilia Coupland COO
 Chief Operating Officer 48 18-12-31
Lena Wange IRC
 Investor Relations Contact - 16-01-31

Members of the board

Members of the board TitleAgeSince
George Frederick Wilkinson BRD
 Director/Board Member 68 19-04-10
James Noble CHM
 Chairman 65 20-04-15
Staffan Lindstrand BRD
 Director/Board Member 62 01-12-31
Michael Matly BRD
 Director/Board Member 42 21-12-31
Charlotte Hansson BRD
 Director/Board Member 55 20-04-15
Christine Rankin BRD
 Director/Board Member 60 22-03-31
Robin Evers BRD
 Director/Board Member - 23-10-26
Mary Pat Christie BRD
 Director/Board Member 61 19-04-10

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 842,971 0 63,000 ( 7.474 %) 78.49 %
Stock B 1 34,710,639 27,907,534 ( 80.40 %) 261,044 ( 0.7521 %)

Shareholders

NameEquities%Valuation
Novo Holdings A/S (Investment Company)
27.78 %
9,643,184 27.78 % 14 M kr
ATP Fondsmaeglerselskab A/S
5.879 %
2,040,633 5.879 % 3 M kr
ATP Arbejdsmarkedets Tillægspension
5.130 %
1,780,633 5.130 % 3 M kr
Anders Walldov
4.610 %
1,600,000 4.610 % 2 M kr
SWEDBANK AB
2.786 %
967,053 2.786 % 1 M kr
Nordnet Pension Insurance
1.570 %
544,889 1.570 % 793 947 kr
Lancelot Asset Management AB
1.440 %
500,000 1.440 % 728 540 kr
Stefan Hansson
1.195 %
414,783 1.195 % 604 372 kr
Sjätte AP-fonden
1.126 %
390,931 1.126 % 569 618 kr
Christer Nystrom
0.9448 %
327,955 0.9448 % 477 857 kr

Holdings

NameEquities%Valuation
OREXO AB
0.85%
 294,866 0.85% 429,643 $

Company contact information

Orexo AB

Virdings allé 32 A

754 50, Uppsala

+46 1 87 80 88 00

http://www.orexo.se
address Orexo AB(ORX)

Group companies

NameCategory and Sector
Pharmacall AB
Logo Pharmacall AB

Pharmacall AB

Investment Banks/BrokersFinance

Part of Orexo AB, Pharmacall AB is a Swedish company that provides securities management services. The private company is located in Sweden.

Investment Banks/Brokers

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Ratings for Orexo AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
OREXO AB Stock Orexo AB
+2.07% 49.8M
MERCK KGAA Stock Merck KGaA
+2.50% 68.35B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.14% 4.78B
YUHAN CORPORATION Stock Yuhan Corporation
+4.07% 3.87B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+19.02% 3.73B
INDIVIOR PLC Stock Indivior PLC
+27.09% 2.52B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-27.48% 2.27B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-25.70% 2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+7.46% 1.95B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ORX Stock
  4. Company Orexo AB